Hematology (all articles)
Cohort Study | Incidence and impact of anticoagulation-associated abnormal menstrual bleeding after VTE
27 Jan, 2023 | 12:04h | UTCInvited Commentary: The burden of heavy menstrual bleeding – Blood
Commentary on Twitter
Incidence and impact of anticoagulation-associated abnormal menstrual bleeding in women after venous thromboembolism https://t.co/IEftFzyvRl pic.twitter.com/m09sP14inN
— Blood Journal (@BloodJournal) October 26, 2022
Post-trial follow-up | Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in early-stage unfavorable Hodgkin Lymphoma
27 Jan, 2023 | 11:58h | UTCCommentaries:
Review | Spotlight on vaccine-induced thrombosis and thrombocytopenia (VITT)
26 Jan, 2023 | 12:46h | UTCSpotlight on vaccine-induced thrombosis and thrombocytopenia (VITT) – Blood
2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis
24 Jan, 2023 | 14:29h | UTCKey Points: 2023 ACC Expert Consensus on Cardiac Amyloidosis – American College of Cardiology
Commentary on Twitter
.@ACCinTouch's 🆕 Expert Consensus Decision Pathway provides practical and timely guidance on the diagnosis and management of cardiac #amyloidosis, with an emphasis on comprehensive multidisciplinary care.
Learn more: https://t.co/1SunbtuQpO#JACC #CardioOnc #CardioTwitter pic.twitter.com/DLvFUpajHC
— JACC Journals (@JACCJournals) January 23, 2023
ASCO Guideline | Management of fever and neutropenia in pediatric patients with cancer and hematopoietic cell transplantation recipients
24 Jan, 2023 | 14:28h | UTC
RCT | Aspirin noninferior to low-molecular-weight heparin for thromboprophylaxis after a fracture
19 Jan, 2023 | 14:30h | UTCAspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: PREVENT CLOT Supports Aspirin for VTE Prevention in Trauma Fractures – TCTMD
M-A | Optimal timing of perioperative chemical thromboprophylaxis in elective major abdominal surgery
19 Jan, 2023 | 13:52h | UTCOptimal Timing of Perioperative Chemical Thromboprophylaxis in Elective Major Abdominal Surgery: A Systematic Review and Meta-analysis – Annals of Surgery (link to abstract – $ for full-text)
Review | Management of patients with lower-risk myelodysplastic syndromes
19 Jan, 2023 | 13:47h | UTCManagement of patients with lower-risk myelodysplastic syndromes – Blood Cancer Journal
Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score
18 Jan, 2023 | 14:37h | UTCSee calculator: https://vtepredict.com/
Commentary on Twitter
The effect of extended anticoagulant treatment for individual patients with venous thromboembolism: the results from the VTE-PREDICT risk score! #venous #thromboembolism #anticoagulant #bleeding #score#EHJ #cardiotwitter @ESC_Journals @escardio
https://t.co/u3NHWyB9rv pic.twitter.com/ifOFxaXV1I— EHJ Editor-in-Chief (@ehj_ed) January 17, 2023
Retrospective study | Supernumerary sex chromosome aneuploidies are associated with increased risk of VTE
18 Jan, 2023 | 14:22h | UTCAssociation of Supernumerary Sex Chromosome Aneuploidies With Venous Thromboembolism – JAMA (free for a limited period)
ESMO Guideline | Venous thromboembolism in cancer patients
15 Jan, 2023 | 20:21h | UTCVenous thromboembolism in cancer patients: ESMO Clinical Practice Guideline – Annals of Oncology
Related:
Cancer-associated venous thromboembolism – Nature Reviews Disease Primers
Infographic: Cancer-associated venous thromboembolism – Nature Reviews Disease Primers
NCCN Guideline: Cancer-Associated Venous Thromboembolic Disease.
ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer
Review: venous and arterial thromboembolism in patients with cancer.
Development and validation of a clinical prediction model for the prediction of 5-year survival in Hodgkin Lymphoma
13 Jan, 2023 | 13:12h | UTCCommentaries:
Commentary from the author on Twitter (thread – click for more)
👉With the dust from #ASH22 settled, we are happy to highlight the inaugural output from the #HoLISTIC consortium: The Advanced-stage cHL International Prognostication Index (A-HIPI) presented at @ASH_hematology w/ simult pub in @ASCO @JCO (https://t.co/em6HENzngk). A thread 1/16 pic.twitter.com/2kicNMBEIj
— Andrew M. Evens, DO, MBA, MSc (@DrAEvens) December 31, 2022
An investigational T-cell therapy shows promise against six viral infections common after stem cell transplants
13 Jan, 2023 | 13:10h | UTC
SR | Laser therapy for retinopathy in sickle cell disease
12 Jan, 2023 | 13:02h | UTCLaser therapy for retinopathy in sickle cell disease – Cochrane Library
Summary: Laser therapy for retinopathy in sickle cell disease – Cochrane Library
Phase 2 RCT | Upfront autologous HSCT vs. carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in multiple myeloma
12 Jan, 2023 | 12:56h | UTCInvited Commentary: Upfront autologous transplantation still improving outcomes in patients with multiple myeloma – The Lancet Haematology
Review | Antithrombotic therapy after bioprosthetic aortic valve replacement
12 Jan, 2023 | 12:51h | UTC
Review | Platelet transfusion for trauma resuscitation
11 Jan, 2023 | 14:08h | UTCPlatelet Transfusion for Trauma Resuscitation – Current Trauma Reports
Special Issue | American Society of Hematology Education Program (series of open-access review articles)
10 Jan, 2023 | 14:26h | UTCHomepage: American Society of Hematology Education Program – Hematology
Chronic lymphocytic leukemia treatment algorithm 2022
10 Jan, 2023 | 14:05h | UTCChronic lymphocytic leukemia treatment algorithm 2022 – Blood Cancer Journal
Updated Guidance | Acute, periprocedural and long-term antithrombotic therapy in older adults.
16 Dec, 2022 | 13:51h | UTCCommentary: Antithrombotic Therapy in Older Adults: Key Points – American College of Cardiology
RCT | Zanubrutinib vs. Ibrutinib in relapsed or refractory chronic lymphocytic leukemia.
16 Dec, 2022 | 13:33h | UTCZanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Zanubrutinib Found Superior to Ibrutinib for CLL and SLL – The ASCO Post
RCT | Hypophosphataemia following ferric derisomaltose vs. ferric carboxymaltose in patients with iron deficiency anemia due to IBD.
16 Dec, 2022 | 13:15h | UTC
Major hemorrhage: past, present and future.
13 Dec, 2022 | 14:05h | UTCMajor haemorrhage: past, present and future – Anaesthesia
Single-arm P1 study | Talquetamab, a T-Cell–redirecting GPRC5D bispecific antibody for multiple myeloma.
12 Dec, 2022 | 12:38h | UTCTalquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Talquetamab, a bifunctional antibody, directs activated T cells to tumor. In this study, up to 70% of the patients with relapsed or refractory myeloma had a response to this agent. https://t.co/OJGHobKG0E pic.twitter.com/53soLSCepA
— NEJM (@NEJM) December 10, 2022
Single-arm P1/2 study | Glofitamab for relapsed or refractory diffuse Large B-Cell Lymphoma.
12 Dec, 2022 | 12:37h | UTCGlofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Glofitamab, a bifunctional antibody, was given to 154 patients with relapsed or refractory DLBCL. Complete response occurred in 39%; most of these responses were ongoing at 12 months. Cytokine release syndrome was common. https://t.co/FWavXlkVXD pic.twitter.com/F4eyYja2E4
— NEJM (@NEJM) December 11, 2022